Skip to main content
ArticleOPEN ACCESS

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study (BMC Cancer. (2017) 17 (332) DOI: 10.1186/s12885-017-3286-5)

BMC Cancer
DOI: 10.1186/s12885-019-5568-6
7Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:

Cite

CITATION STYLE

APA

Sekulic, A., Migden, M. R., Basset-Seguin, N., Garbe, C., Gesierich, A., Lao, C. D., … Hauschild, A. (2019, April 18). Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study (BMC Cancer. (2017) 17 (332) DOI: 10.1186/s12885-017-3286-5). BMC Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12885-019-5568-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free